Private Advisor Group LLC raised its position in Novartis AG (NYSE:NVS) by 11.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,518 shares of the company’s stock after purchasing an additional 2,724 shares during the period. Private Advisor Group LLC’s holdings in Novartis were worth $2,267,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in NVS. Geode Capital Management LLC boosted its holdings in Novartis by 19.8% in the 1st quarter. Geode Capital Management LLC now owns 18,918 shares of the company’s stock valued at $1,405,000 after purchasing an additional 3,125 shares during the period. Somerset Trust Co lifted its holdings in shares of Novartis by 7.6% during the 2nd quarter. Somerset Trust Co now owns 14,384 shares of the company’s stock worth $1,201,000 after acquiring an additional 1,017 shares during the last quarter. Chevy Chase Trust Holdings Inc. lifted its holdings in shares of Novartis by 5.9% during the 2nd quarter. Chevy Chase Trust Holdings Inc. now owns 336,503 shares of the company’s stock worth $28,088,000 after acquiring an additional 18,806 shares during the last quarter. Leavell Investment Management Inc. bought a new stake in shares of Novartis during the 2nd quarter worth $318,000. Finally, Chesley Taft & Associates LLC lifted its holdings in shares of Novartis by 1.3% during the 2nd quarter. Chesley Taft & Associates LLC now owns 60,666 shares of the company’s stock worth $5,064,000 after acquiring an additional 794 shares during the last quarter. 10.87% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on NVS shares. Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a report on Tuesday, September 19th. BidaskClub raised shares of Novartis from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Cowen set a $90.00 price objective on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, August 9th. Leerink Swann lifted their price objective on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis in a report on Tuesday, October 10th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and a consensus price target of $85.32.
Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm’s revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.23 EPS. equities research analysts predict that Novartis AG will post 4.75 EPS for the current fiscal year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.